Revitalist Announces Strategic Partnership with Sama Therapeutics to Advance Digital Human AI Agents for Precision Mental Health
Revitalist Lifestyle and Wellness (CSE: CALM) (OTC: RVLWF) has partnered with Sama Therapeutics to launch an advanced Digital Human AI Agent for mental health assessments. This AI, modeled after Revitalist CEO Kathryn Walker, utilizes the company's Federal Unit Scale (FUS) for risk mitigation assessments. The FUS was validated through a study of 11,798 participants, showing strong psychometric properties.
The Sama AI Agent platform can create digital avatars of healthcare providers, communicating in over 100 languages and capturing audiovisual biomarkers for precise data collection. This innovation aims to enhance mental health care accessibility globally. The collaboration combines Revitalist's expertise in mental health care with Sama's advanced AI technology, potentially revolutionizing patient care and clinical research in neuropsychiatry.
Revitalist Lifestyle and Wellness (CSE: CALM) (OTC: RVLWF) ha stretto una partnership con Sama Therapeutics per lanciare un avanzato Agente AI Umano Digitale per valutazioni di salute mentale. Questa AI, modellata sulla CEO di Revitalist Kathryn Walker, utilizza la Federal Unit Scale (FUS) dell'azienda per valutazioni di mitigazione del rischio. La FUS è stata convalidata attraverso uno studio su 11.798 partecipanti, evidenziando solide proprietà psicometriche.
La piattaforma Sama AI Agent può creare avatar digitali di fornitori di assistenza sanitaria, comunicando in oltre 100 lingue e catturando biomarcatori audiovisivi per una raccolta dati precisa. Questa innovazione mira a migliorare l'accessibilità alla salute mentale a livello globale. La collaborazione combina l'esperienza di Revitalist nella salute mentale con la tecnologia avanzata AI di Sama, potenzialmente rivoluzionando l'assistenza ai pazienti e la ricerca clinica in neuropsichiatria.
Revitalist Lifestyle and Wellness (CSE: CALM) (OTC: RVLWF) ha establecido una asociación con Sama Therapeutics para lanzar un avanzado Agente Humano Digital AI para evaluaciones de salud mental. Esta IA, modelada según la CEO de Revitalist Kathryn Walker, utiliza la Federal Unit Scale (FUS) de la compañía para evaluaciones de mitigación de riesgos. La FUS fue validada a través de un estudio con 11,798 participantes, mostrando fuertes propiedades psicométricas.
La plataforma Sama AI Agent puede crear avatares digitales de proveedores de atención médica, comunicándose en más de 100 idiomas y capturando biomarcadores audiovisuales para una recolección de datos precisa. Esta innovación tiene como objetivo mejorar la accesibilidad a la atención de salud mental en todo el mundo. La colaboración combina la experiencia de Revitalist en salud mental con la avanzada tecnología AI de Sama, potencialmente revolucionando la atención al paciente y la investigación clínica en neuropsiquiatría.
Revitalist Lifestyle and Wellness (CSE: CALM) (OTC: RVLWF)는 Sama Therapeutics와 협력하여 정신 건강 평가를 위한 고급 디지털 인간 AI 에이전트를 출시했습니다. 이 AI는 Revitalist의 CEO인 Kathryn Walker를 모델로 하여 회사의 Federal Unit Scale (FUS)를 사용하여 위험 완화 평가를 수행합니다. FUS는 11,798명의 참여자를 대상으로 한 연구를 통해 검증되어 강력한 심리측정 특성을 보여주었습니다.
Sama AI Agent 플랫폼은 의료 제공자의 디지털 아바타를 생성할 수 있으며, 100개 이상의 언어로 의사소통하고 정밀한 데이터 수집을 위해 시청각 바이오마커를 포착합니다. 이 혁신은 전 세계적으로 정신 건강 관리의 접근성을 향상시키는 것을 목표로 하고 있습니다. 이 협력은 정신 건강 관리에서 Revitalist의 전문성과 Sama의 고급 AI 기술을 결합하여 환자 치료와 신경정신의학 분야의 임상 연구를 혁신할 가능성을 가지고 있습니다.
Revitalist Lifestyle and Wellness (CSE: CALM) (OTC: RVLWF) a établi un partenariat avec Sama Therapeutics pour lancer un agent IA humain numérique avancé pour les évaluations de santé mentale. Cette IA, modélisée d'après la PDG de Revitalist, Kathryn Walker, utilise la Federal Unit Scale (FUS) de l'entreprise pour des évaluations de réduction des risques. La FUS a été validée à travers une étude de 11 798 participants, montrant de solides propriétés psychométriques.
La plateforme Sama AI Agent peut créer des avatars numériques de fournisseurs de soins de santé, communiquant dans plus de 100 langues et capturant des biomarqueurs audiovisuels pour une collecte de données précise. Cette innovation vise à améliorer l'accessibilité des soins de santé mentale à l'échelle mondiale. La collaboration combine l'expertise de Revitalist dans le domaine de la santé mentale avec la technologie IA avancée de Sama, révolutionnant potentiellement les soins aux patients et la recherche clinique en neuropsychiatrie.
Revitalist Lifestyle and Wellness (CSE: CALM) (OTC: RVLWF) hat eine Partnerschaft mit Sama Therapeutics geschlossen, um einen fortschrittlichen digitalen menschlichen KI-Agenten für psychische Gesundheitsbewertungen zu starten. Diese KI, die auf Revitalist-CEO Kathryn Walker modelliert ist, nutzt die Federal Unit Scale (FUS) des Unternehmens für Risikominderungsbewertungen. Die FUS wurde durch eine Studie mit 11.798 Teilnehmern validiert und zeigt starke psychometrische Eigenschaften.
Die Sama AI-Agent-Plattform kann digitale Avatare von Gesundheitsdienstleistern erstellen, die in über 100 Sprachen kommunizieren und audiovisuellen Biomarker für eine präzise Datenerfassung erfassen. Diese Innovation zielt darauf ab, den Zugang zur psychischen Gesundheitsversorgung weltweit zu verbessern. Die Zusammenarbeit verbindet die Expertise von Revitalist im Bereich der psychischen Gesundheit mit der fortschrittlichen KI-Technologie von Sama, was das Potenzial hat, die Patientenversorgung und klinische Forschung in der Neuropsychiatrie zu revolutionieren.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2024) - Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO), a leader in comprehensive mental health and wellness care, is excited to announce a research and patient care partnership with Sama Therapeutics for expanding access through novel technology. This collaboration marks the release of an advanced, proprietary Digital Human Artificial Intelligence Agent designed to enhance mental health assessments worldwide.
Modeled after Revitalist CEO Kathryn Walker, her AI Agent engages patients in conversational dialogue and implements the company's proprietary risk mitigation assessment, the Federal Unit Scale (FUS). This novel mental health screening tool is designed to minimize potential distress in vulnerable populations while gathering essential clinical data. In a collaborative effort, Sama's domain expert, Professor Tyler M. Moore rigorously validated the FUS through an analysis of 11,798 participants, demonstrating strong psychometric properties, including internal consistency, unidimensionality, and robust convergent and criterion validity with established measures.
The Sama AI Agent platform can create and stream individual, lifelike, digital human avatars of entire multispecialty teams of healthcare providers, capable of communicating in over 100 languages. Utilizing state-of-the-art algorithms and integrations, the AI Agent features an immersive experience which captures audiovisual biomarkers (facial expressions, speech patterns, and other forms of body language), allowing for precise and objective data collection as part of routine healthcare evaluation. This innovation is set to redefine mental health care accessibility and engagement on a global scale.
"The partnership between Revitalist and Sama is an excellent synergy," said Dr. Shobi Ahmed, CEO and founder of Sama Therapeutics. "By combining our expertise, we are poised to deliver the highest standard of patient care and clinical research with exceptional efficiency, integrating medically and ethically sound artificial intelligence in neuropsychiatry. The treatment outcomes data we've analyzed and submitted for publication is rigorous and groundbreaking. We are enthusiastic about the powerful impact our collaboration with Revitalist will have, driven by mutual thought leadership in precision medicine."
"Our partnership with Sama Therapeutics represents a major step forward in expanding access to high-quality mental health care," said Kathryn Walker, CEO of Revitalist. "By integrating advanced AI technology, we are not only enhancing our ability to provide accurate assessments but also empowering individuals globally with tools to better understand and manage their mental health. We are excited to see the positive impact this technology will have on communities worldwide."
About Revitalist Lifestyle and Wellness Ltd.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is a mental health and wellness company focused on comprehensive care in the ketamine wellness space offering innovative, evidenced based services. The Company operates through physical locations and virtual offices across 35 states.
Founded and led by Kathryn Walker, an advanced provider in the psychedelic space, Revitalist is at the forefront of this emerging field. Visit Revitalist.com for more information.
About Sama Therapeutics
Sama Therapeutics is a leading innovator in AI-powered precision medicine. The company's proprietary iMAGiNE™ platform integrates predictive biomarkers and Digital Human AI Agents to deliver personalized brain health assessments, accelerating the development of safer and more effective therapeutics for complex patient populations.
By integrating generative AI with computational life sciences, Sama is redefining "software as a medical device" across cognitive, affective, interoceptive, and substance use disorders. The company's agile SaaS approach leverages cutting-edge technologies including digital twins, deep phenotyping, causal inference, and precision clinical trials to analyze the transdiagnostic efficacy of pharmaceutical and neurostimulation modalities.
Sama Therapeutics' mission is to unlock brain health through integrative neurotechnology, transforming psychiatric and neurological medicine. Visit Sama.ac for more information.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to known and unknown risks, uncertainties and assumptions and accordingly, actual results and future events could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. All statements other than statements of present or historical fact are forward-looking statements, including statements with respect to Revitalist™' future business plans and partnerships. Forward-looking statements include words or expressions such as "proposed", "anticipated", "will", "subject to", "near future", "in the event", "would", "expect", "prepared to" and other similar words or expressions and include, but are not limited to: the ability of Revitalist™ to secure patent protection; the regulatory environment in which Revitalist™ operates; the ability of Revitalist™ to carry out its business plans and unforeseen challenges in carrying out such plans; trends in the future use of psychedelics; general business, economic, competitive, political and social uncertainties; the state of capital markets; and other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We disclaim any obligation to update or revise these forward-looking statements, except as required by applicable law.
PR Contact
Kristina Spionjak
pr@hlthcommunications.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222639
FAQ
What is the new partnership announced by Revitalist (RVLWF) on September 9, 2024?
How does Revitalist's (RVLWF) new AI Agent work for mental health assessments?
What capabilities does the Sama AI Agent platform offer for Revitalist (RVLWF)?
How was the Federal Unit Scale (FUS) used by Revitalist (RVLWF) validated?
What is the goal of Revitalist's (RVLWF) partnership with Sama Therapeutics announced on September 9, 2024?
